

# **Veklury (remdesivir) Recall Alert**

Date of Notice: 12/03/2021

## **Brief Description of Recall Alert**

Gilead Sciences Inc. is voluntarily recalling two lots of Veklury (remdesivir 100 mg for injection). Gilead Sciences Inc. received a customer complaint, confirmed by investigation, of the presence of glass particulates.

Risk Statement: The administration of an injectable product that contains glass particulates may result in local irritation or swelling in response to the foreign material. If the glass particulate reaches the blood vessels, it can travel to various organs and block blood vessels in the heart, lungs, or brain, which can cause stroke and even lead to death.

### **Affected Products**

Drug Name & Strength	NDC	Lot	Expiration Date
Veklury	61958-2901-02	2141001-1A	01/2024
(remdesivir 100mg for injection)		2141002-1A	01/2024

#### **Prescriber Information**

Gilead is notifying its distributors and customers and is facilitating the return of any remaining vials from the affected lots. Hospitals that have Veklury, which is being recalled, should stop using the affected lots and return the product vials per the instructions.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. To date, Gilead Sciences Inc. has not received any reports of adverse events related to this recall.

- Complete and submit the report <u>Online</u>
- Regular Mail or Fax: <u>Download form</u> or call 1-800-332-1088 to request a reporting form, then
  complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

#### **Member Information**

Members with questions regarding this recall can contact Gilead Medical Information at 1-866-633-4474 Monday to Friday 6am - 4pm PST or through their website at www.askgileadmedical.com. Members should contact their doctor or healthcare provider if they have experienced any problems that are thought to be related to using this drug product.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.

© 2020 RxAdvance Corporation. Confidential and Proprietary.

Page 1 of 2 v 2.7.04.1



## **RxAdvance Response**

Members should contact their doctors or healthcare provider if they have experienced any problems that are thought to be related to using this product.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.

© 2020 RxAdvance Corporation. Confidential and Proprietary.

Page 2 of 2 v 2.7.04.1